These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
189 related articles for article (PubMed ID: 36710464)
41. A crowdsourcing survey study on the subjective effects of delta-8-tetrahydrocannabinol relative to delta-9-tetrahydrocannabinol and cannabidiol. Bergeria CL; Strickland JC; Spindle TR; Kalaba M; Satyavolu PU; Feldner M; Vandrey R; Bonn-Miller M; Peters EN; Weerts E Exp Clin Psychopharmacol; 2023 Apr; 31(2):312-317. PubMed ID: 35467921 [TBL] [Abstract][Full Text] [Related]
42. Absence of Relevant Thermal Conversion of Cannabidiol to Tetrahydrocannabinol in E-Cigarette Vapor and Low-Tetrahydrocannabinol Cannabis Smoke. Hindelang P; Scharinger A; Golombek P; Laible M; Tamosaite S; Walch SG; Lachenmeier DW Cannabis Cannabinoid Res; 2022 Oct; 7(5):616-620. PubMed ID: 36169637 [No Abstract] [Full Text] [Related]
43. 'Synthetic cannabis': A dangerous misnomer. Darke S; Banister S; Farrell M; Duflou J; Lappin J Int J Drug Policy; 2021 Dec; 98():103396. PubMed ID: 34343944 [TBL] [Abstract][Full Text] [Related]
44. An evaluation of postmortem concentrations of Δ Hoffman MA; Trochta A; Gary RD; Fitzgerald RL; McIntyre IM Forensic Sci Int; 2020 Oct; 315():110414. PubMed ID: 32738674 [TBL] [Abstract][Full Text] [Related]
45. Impact of early-life lead exposure on adult delta-9-tetrahydrocannabinol sensitivity in male and female C57BL6/J mice. Garcy D; Boehm SL Neurotoxicol Teratol; 2023; 100():107290. PubMed ID: 37690674 [TBL] [Abstract][Full Text] [Related]
46. Highway to hell or magic smoke? The dose-dependence of Δ Kubilius RA; Kaplick PM; Wotjak CT Learn Mem; 2018 Sep; 25(9):446-454. PubMed ID: 30115766 [TBL] [Abstract][Full Text] [Related]
47. Intrathecal Actions of the Cannabis Constituents Δ(9)-Tetrahydrocannabinol and Cannabidiol in a Mouse Neuropathic Pain Model. Casey SL; Mitchell VA; Sokolaj EE; Winters BL; Vaughan CW Int J Mol Sci; 2022 Aug; 23(15):. PubMed ID: 35955774 [TBL] [Abstract][Full Text] [Related]
48. How should policymakers regulate the tetrahydrocannabinol content of cannabis products in a legal market? Hall W; Leung J; Carlini BH Addiction; 2023 Jun; 118(6):998-1003. PubMed ID: 36662648 [TBL] [Abstract][Full Text] [Related]
49. Separate and combined effects of the cannabinoid agonists nabilone and Δ⁹-THC in humans discriminating Δ⁹-THC. Lile JA; Kelly TH; Hays LR Drug Alcohol Depend; 2011 Jul; 116(1-3):86-92. PubMed ID: 21227600 [TBL] [Abstract][Full Text] [Related]
50. One-pot heterogeneous synthesis of Δ(3)-tetrahydrocannabinol analogues and xanthenes showing differential binding to CB(1) and CB(2) receptors. Rosati O; Messina F; Pelosi A; Curini M; Petrucci V; Gertsch J; Chicca A Eur J Med Chem; 2014 Oct; 85():77-86. PubMed ID: 25072877 [TBL] [Abstract][Full Text] [Related]
51. Potency testing of up to twenty cannabinoids by liquid chromatography diode array detector with optional electrospray ionization time-of-flight mass spectrometry. Song L; Valenzuela G; Carlson S; Dodson Z; Adisa M Anal Chim Acta; 2022 May; 1207():339827. PubMed ID: 35491034 [TBL] [Abstract][Full Text] [Related]
52. Delta-8 Tetrahydrocannabinol Exposures Reported to US Poison Centers: Variations Among US States and Regions and Associations with Public Policy. Smith GA; Burgess A; Badeti J; Rine NI; Gaw CE; Middelberg LK; Spiller HA; Hays HL J Med Toxicol; 2024 Oct; 20(4):389-400. PubMed ID: 39168936 [TBL] [Abstract][Full Text] [Related]
53. Association of Tetrahydrocannabinol Content and Price in Herbal Cannabis Products Offered by Dispensaries in California: A Purview of Consumers/Patients. Dobbins M; Rakkar M; Cunnane K; Pennypacker SD; Wagoner KG; Reboussin BA; Romero-Sandoval EA Front Public Health; 2022; 10():893009. PubMed ID: 35784239 [TBL] [Abstract][Full Text] [Related]
54. Potency of Δ Potter DJ; Hammond K; Tuffnell S; Walker C; Di Forti M Drug Test Anal; 2018 Apr; 10(4):628-635. PubMed ID: 29441730 [TBL] [Abstract][Full Text] [Related]
55. Cannabis regulatory system in European Union countries, forensic concept of "doping dose" and medico-legal implications. Cioffi A; Cecannecchia C; David MC; Cipolloni L; Santurro A Med Leg J; 2023 Sep; 91(3):128-135. PubMed ID: 37293768 [TBL] [Abstract][Full Text] [Related]
56. Adulteration of low-delta-9-tetrahydrocannabinol products with synthetic cannabinoids: Results from drug checking services. Monti MC; Zeugin J; Koch K; Milenkovic N; Scheurer E; Mercer-Chalmers-Bender K Drug Test Anal; 2022 Jun; 14(6):1026-1039. PubMed ID: 34997693 [TBL] [Abstract][Full Text] [Related]
57. Mechanisms of cannabis impairment: Implications for modeling driving performance. Burt TS; Brown TL; Milavetz G; McGehee DV Forensic Sci Int; 2021 Nov; 328():110902. PubMed ID: 34634690 [TBL] [Abstract][Full Text] [Related]
58. [Dependence and Cytotoxicity of Components of Cannabis]. Funada M; Tomiyama KI Yakugaku Zasshi; 2020; 140(2):205-214. PubMed ID: 32009044 [TBL] [Abstract][Full Text] [Related]
59. Investigation of phase II metabolism of 11-hydroxy-Δ-9-tetrahydrocannabinol and metabolite verification by chemical synthesis of 11-hydroxy-Δ-9-tetrahydrocannabinol-glucuronide. Hassenberg C; Clausen F; Hoffmann G; Studer A; Schürenkamp J Int J Legal Med; 2020 Nov; 134(6):2105-2119. PubMed ID: 32808050 [TBL] [Abstract][Full Text] [Related]
60. A naturalistic study of orally administered vs. inhaled legal market cannabis: cannabinoids exposure, intoxication, and impairment. Bidwell LC; Karoly HC; Torres MO; Master A; Bryan AD; Hutchison KE Psychopharmacology (Berl); 2022 Feb; 239(2):385-397. PubMed ID: 34708254 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]